PHARMACIE DU STUYVENBERGH (Private limited company)
PHARMACIE DU STUYVENBERGH is a Belgian company registered with the Crossroads Bank for Enterprises under enterprise number 0832.520.712. It was founded on 06-01-2011. Its registered office is in Brussels. Its main activity is: Financial service activities, except insurance and pension funding. Its annual accounts for 2025 report equity of € 493 505 and a profit of € 84 763. These accounts report 1 full-time equivalents. Addrly gives it a financial health grade of B, on a scale from A (safest) to E (most at risk). It filed its annual accounts within the legal deadline for 3 of its last 4 financial years.
Information last updated on 21-10-2026.
Company information
Key figures of PHARMACIE DU STUYVENBERGH
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
Profit / lossiWhat the period earned after taxes. A negative amount is a loss. | € 84 763-21 % | € 107 737-18 % | € 131 226+503 % | € 21 747 |
EquityiWhat belongs to the shareholders: capital contributed, reserves and profits kept in the company. | € 493 505+14 % | € 433 743+33 % | € 326 006+67 % | € 194 780 |
Total assetsiEverything the company owns. Equal to total equity and liabilities, which says how it is financed. | € 766 510-8 % | € 829 242+1 % | € 824 347+76 % | € 468 749 |
Gross marginiSales and other operating income, minus purchases of goods and services. What is left to pay the staff and everything else. | € 278 523+1 % | € 276 735-10 % | € 305 928+1 112 % | € 25 237 |
Employees (FTE)iAverage number of workers over the period, in full-time equivalents. | 10 % | 1 | - | - |
Financial estimate
Similar companies
Other companies in the same activity in Brussels.
| Company | Town |
|---|---|
| ACERTA | 1020 Bruxelles |
| Moore Belgium | 1020 Bruxelles |
| Finance et Industrie | 1020 Bruxelles |
| Belgo Mart Investors | 1020 Bruxelles |
| BUFRAPEX | 1020 Bruxelles |
| DUCROS DISTRIBUTION BENELUX | 1020 Bruxelles |
| Maatschappij voor Krediet en Financiering | 1020 Bruxelles |
| DEFICOM GROUP | 1020 Bruxelles |
Frequently asked questions
Is PHARMACIE DU STUYVENBERGH still active? Yes. The Crossroads Bank for Enterprises lists PHARMACIE DU STUYVENBERGH as active.
What is the VAT number of PHARMACIE DU STUYVENBERGH? The VAT number of PHARMACIE DU STUYVENBERGH is BE 0832.520.712.
When was PHARMACIE DU STUYVENBERGH founded? PHARMACIE DU STUYVENBERGH was founded on 06-01-2011.
What is the address of PHARMACIE DU STUYVENBERGH? The current registered office of PHARMACIE DU STUYVENBERGH is Rue Alfred Stevens 102/104, 1020 Bruxelles.
When did PHARMACIE DU STUYVENBERGH last file annual accounts? The latest annual accounts of PHARMACIE DU STUYVENBERGH were filed on 23-06-2026.
Does PHARMACIE DU STUYVENBERGH file its annual accounts on time? PHARMACIE DU STUYVENBERGH filed its annual accounts within the legal deadline for 3 of its last 4 financial years. Late: 2022.
How many employees does PHARMACIE DU STUYVENBERGH have? PHARMACIE DU STUYVENBERGH employs 1 full-time equivalents according to its most recent annual accounts.
Is PHARMACIE DU STUYVENBERGH financially healthy? Addrly gives PHARMACIE DU STUYVENBERGH a financial health grade of B, on a scale from A (safest) to E (most at risk). The failure probability and the indicators behind it are visible with a free account.
Is PHARMACIE DU STUYVENBERGH profitable? The annual accounts of PHARMACIE DU STUYVENBERGH for 2025 show a profit of € 84 763.
What is the equity of PHARMACIE DU STUYVENBERGH? The equity of PHARMACIE DU STUYVENBERGH was € 493 505 at the close of the 2025 financial year.
Who are the directors of PHARMACIE DU STUYVENBERGH? The annual accounts of PHARMACIE DU STUYVENBERGH record 1 mandate. The name, role and dates are visible with a free account.
Can PHARMACIE DU STUYVENBERGH receive Peppol e-invoices? Yes. PHARMACIE DU STUYVENBERGH is registered on the Peppol network and can receive structured electronic invoices.
What does PHARMACIE DU STUYVENBERGH do? The main activity of PHARMACIE DU STUYVENBERGH is: Financial service activities, except insurance and pension funding.